AstraZeneca reported mixed Q2 2026 results, beating earnings but missing revenue expectations. The company also announced disappointing Phase 3 trial results for Ultomiris in HSCT-TMA and Sone-Ve in gastric cancers, though Sone-Ve did show an overall survival benefit. Despite these setbacks, AstraZeneca reiterated its full-year guidance and $80 billion revenue ambition, suggesting management views these as speed bumps rather than major derailments.
AstraZeneca's Q2 2026 results presented a mixed picture, with an earnings beat but a revenue miss. More significantly, the company disclosed disappointing Phase 3 trial results for two key experimental therapies: Ultomiris failed to meet its primary endpoint in HSCT-TMA, and Sone-Ve, while showing an overall survival benefit, fell short on progression-free survival in gastric cancers. These pipeline setbacks could temper investor enthusiasm for AstraZeneca's growth prospects, particularly for Ultomiris, a leading rare disease drug. However, the company's reiteration of its full-year guidance and ambitious $80 billion revenue target suggests management believes these are manageable challenges, with a strong oncology portfolio and other pipeline readouts expected. The short-term impact could be negative sentiment due to the trial failures, but the long-term outlook depends on the success of other pipeline assets and continued growth in established segments.